Navigation Links
New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Aug. 15 (HealthDay News) -- A new investigational drug known as enzalutamide adds an average of five months to the lives of men with advanced prostate cancer, a new study has found.

This is such a significant finding that the trial was stopped early so men receiving a placebo could opt to take enzalutamide.

"We found a hormonal drug prolongs the lives of men who have failed traditional hormones as well as chemotherapy," said lead researcher Dr. Howard Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City.

In addition, these results show that even after failing regular hormone therapy these tumors can still react to a hormone-based treatment, he said.

Scher said he believes enzalutamide might be even more effective if used in men with earlier stages of prostate cancer. Trials testing that theory are under way, he said.

One of the reasons for testing the drug in late-stage cancer is to speed U.S. Food and Drug Administration approval, Scher said.

The results of the study were published online Aug. 15 in the New England Journal of Medicine.

In this phase 3 trial, nearly 1,200 men with advanced prostate cancer were randomly selected to take either enzalutamide, which is taken orally, or a placebo. The men had already undergone chemotherapy, the researchers noted.

Compared to those on placebo, men taking enzalutamide lived an average of nearly five months longer and their risk of dying was reduced by 37 percent, the researchers found.

The drug is not without side effects, however, the most serious of which were seizures.

"[Seizures] occurred in five of the 800 patients who received the drug," Scher said. Many of these patients had factors making them susceptible to seizures, he said.

Enzalutamide patients also reported hot flashes, fatigue and diarrhea.

Whether the drug will cause side effects like those seen with regular hormone therapy isn't yet known, Scher said. That's something the current trials may reveal.

The possible side effects can reduce patient's quality of life and include constipation or diarrhea, nausea, loss of or decrease in appetite, dizziness or headache, trouble sleeping, impotence, and decreased sex drive.

Enzalutamide is a type of hormonal therapy that, through another pathway, acts like traditional hormone therapy. It was created to help men who develop resistance to regular hormone therapy and go on to develop an aggressive cancer called castration-resistant prostate cancer, the most advanced form of the disease, Scher said.

Researchers found that men build resistance to hormone therapy because the tumor increases the production of androgen (a male hormone) receptors, he added.

Enzalutamide binds to androgen receptors in cancer cells, blocking the ability of these receptors to promote cancer growth, Scher explained.

If approved, enzalutamide would join a similar drug, abiraterone (Zytiga), as a new treatment for prostate cancer that is resistant to traditional hormone therapy.

Although it is too early to know how much enzalutamide will cost, the wholesale cost of abiraterone is about $5,000 a month, according to Bloomberg News. The retail cost is, of course, higher.

"This is good news for men with advanced prostate cancer," said Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston.

"It's likely a drug that will be FDA approved," he said.

D'Amico cautioned, however, that if the drug is used in men with early prostate cancer who are prone to seizures, it needs to be carefully monitored.

"The bottom line is, it's good news," D'Amico said. "I predict in the next five to seven years we will be using drugs like this as opposed to what we currently use to treat men with earlier-stage disease."

More information

To learn more about prostate cancer, visit the American Cancer Society.

SOURCES: Howard Scher, M.D., chief, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York City; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; May 17, 2012, Bloomberg News; Aug. 15, 2012, New England Journal of Medicine online

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Off-Label Drug Use Appears Common
2. Exercise Appears to Ease Nerve-Damage Pain in Rat Study
3. New Pill Appears Effective, Safe for Ulcerative Colitis: Study
4. Healthy Behaviors Extend Life After Cancer, Experts Say
5. Exercise and a healthy diet of fruits and vegetables extends life expectancy in women in their 70s
6. New Melanoma Drug May Extend Survival
7. New treatment protocol extends survival in some cases of once inoperable pancreatic cancer
8. Spaceflight may extend the lifespan of microscopic worm
9. Gene therapy treatment extends lives of mice with fatal disease, MU study finds
10. Experimental drug may extend therapeutic window for stroke
11. Golden age of prostate cancer treatment hailed as fourth drug in 2 years extends life
Post Your Comments:
Related Image:
New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
(Date:11/25/2015)... ... November 25, 2015 , ... As ... Water For Empowerment ™ attracts volunteers together who want to combine talents and ... as key stakeholders in the process. The non-profit launched its first major fundraiser ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and ... of traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... companies, has been recognized once again for its stellar workplace culture with the ... Work.” , Medical Solutions’ Cincinnati office was named a finalist in ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology: